Investigator-assessed response
| . | N = 101 . |
|---|---|
| Best response, n (%, 95% CI) | |
| Objective response | 84 (83, 74-90) |
| CR | 59 (58, 48-68) |
| PR | 25 (25, 17-34) |
| SD | 10 (10, 5-17) |
| PD | 5 (5, 2-11) |
| Not done | 2 (2, 0-7) |
| Ongoing response, n (%) | 31 (31) |
| CR | 30 (30) |
| PR | 1 (1) |
| DOR (95% CI) | |
| Median DOR, mos | 11.1 (4.2-51.3) |
| Median duration of CR, mos | 62.2 (12.9-NE) |
| Median duration of PR, mos | 1.9 (1.3-2.1) |
| . | N = 101 . |
|---|---|
| Best response, n (%, 95% CI) | |
| Objective response | 84 (83, 74-90) |
| CR | 59 (58, 48-68) |
| PR | 25 (25, 17-34) |
| SD | 10 (10, 5-17) |
| PD | 5 (5, 2-11) |
| Not done | 2 (2, 0-7) |
| Ongoing response, n (%) | 31 (31) |
| CR | 30 (30) |
| PR | 1 (1) |
| DOR (95% CI) | |
| Median DOR, mos | 11.1 (4.2-51.3) |
| Median duration of CR, mos | 62.2 (12.9-NE) |
| Median duration of PR, mos | 1.9 (1.3-2.1) |
PD, progressive disease; PR, partial response; SD, stable disease.